Rosiglitazone ameliorates astrocyte over-activation and inflammatory cytokine release induced by global cerebral ischemia/reperfusion

Ren,Shanling; Xu,Yan; Lv,Dongwei; Zhang,Lei

doi:10.3892/etm.2016.2975

Rosiglitazone ameliorates astrocyte over-activation and inflammatory cytokine release induced by global cerebral ischemia/reperfusion

Authors:
- Shanling Ren
- Yan Xu
- Dongwei Lv
- Lei Zhang
View Affiliations

Affiliations: Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: January 11, 2016 https://doi.org/10.3892/etm.2016.2975
Pages: 1071-1076

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Global cerebral ischemia (GCI) is a leading cause of mortality worldwide and remains the primary cause of long-term neurological disability. Astrocyte over-activation and extensive neuron loss in the ischemic brain are the characteristic pathological features of cerebral ischemia. Rosiglitazone (RSG) is a peroxisome-proliferating activating receptor-γ agonist known for its anti‑inflammatory activity. Previous studies have suggested that RSG is able to exert neuroprotection in numerous acute and chronic brain injury models. However, whether RSG treatment is involved in astrocyte over‑activation and inflammatory reaction in the cortex remains unclear. The aim of the present study was to investigate whether RSG treatment improved functional impairment induced following GCI and protected against cortex neuron loss, and to elucidate the potential mechanisms underlying these functions. Rats were randomly divided into three groups: Sham‑operated, GCI and RSG treatment groups. The RSG treatment group was treated with 2 mg/kg RSG immediately following GCI. The results demonstrated that RSG treatment significantly reduced infarct volume and neuron survival rates in addition to increasing function recovery. Furthermore, these results correlate with a reduction in astrocyte over‑activation and inflammatory cytokines in the rat cortex. However, no significant changes in glutamate transporter‑1 expression levels were observed following RSG treatment compared with the GCI rats. The results of this investigation provide in vivo evidence that RSG significantly protected rats against ischemia‑reperfusion‑induced brain injury. In addition, RSG may exert neuroprotective effects by inhibiting astrocyte over‑activation, and thereby reducing the levels of inflammatory cytokines in the GCI-injured brain. All data revealed that RSG may be a potential neuroprotective agent for cerebral ischemia.

View Figures

View References

1	Cao Y, Mao X, Sun C, Zheng P, Gao J, Wang X, Min D, Sun H, Xie N and Cai J: Baicalin attenuates global cerebral ischemia/reperfusion injury in gerbils via anti-oxidative and anti-apoptotic pathways. Brain Res Bull. 85:396–402. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kristián T and Siesjö BK: Calcium in ischemic cell death. Stroke. 29:705–718. 1998. View Article : Google Scholar : PubMed/NCBI
3	Love S: Oxidative stress in brain ischemia. Brain Pathol. 9:119–131. 1999. View Article : Google Scholar : PubMed/NCBI
4	Choi DW and Rothman SM: The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 13:171–182. 1990. View Article : Google Scholar : PubMed/NCBI
5	Huang J, Upadhyay UM and Tamargo RJ: Inflammation in stroke and focal cerebral ischemia. Surg Neurol. 66:232–245. 2006. View Article : Google Scholar : PubMed/NCBI
6	Shamloo M, Rytter A and Wieloch T: Activation of the extracellular signal-regulated protein kinase cascade in the hippocampal CA1 region in a rat model of global cerebral ischemic preconditioning. Neuroscience. 93:81–88. 1999. View Article : Google Scholar : PubMed/NCBI
7	Mehta SL, Manhas N and Raghubir R: Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev. 54:34–66. 2007. View Article : Google Scholar : PubMed/NCBI
8	Liu S, Levine SR and Winn HR: Targeting ischemic penumbra: Part I-from pathophysiology to therapeutic strategy. J Exp Stroke Transl Med. 3:47–55. 2010. View Article : Google Scholar : PubMed/NCBI
9	Ogata K and Kosaka T: Structural and quantitative analysis of astrocytes in the mouse hippocampus. Neuroscience. 113:221–233. 2002. View Article : Google Scholar : PubMed/NCBI
10	Pekny M and Nilsson M: Astrocyte activation and reactive gliosis. Glia. 50:427–434. 2005. View Article : Google Scholar : PubMed/NCBI
11	Swanson RA, Ying W and Kauppinen TM: Astrocyte influences on ischemic neuronal death. Curr Mol Med. 4:193–205. 2004. View Article : Google Scholar : PubMed/NCBI
12	Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S and Dandona P: Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 89:2728–2735. 2004. View Article : Google Scholar : PubMed/NCBI
13	Escribano L, Simón A-M, Pérez-Mediavilla A, Salazar-Colocho P, Del Río J and Frechilla D: Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun. 379:406–410. 2009. View Article : Google Scholar : PubMed/NCBI
14	Yi JH, Park SW, Brooks N, Lang BT and Vemuganti R: PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 1244:164–172. 2008. View Article : Google Scholar : PubMed/NCBI
15	Zhang Q, Hu W, Meng B and Tang T: PPAR γ agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats. Neurol Res. 32:852–859. 2010. View Article : Google Scholar : PubMed/NCBI
16	Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH and Chen J: Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem. 97:435–448. 2006. View Article : Google Scholar : PubMed/NCBI
17	Al Rouq F and El Eter E: PPAR-γ activator induces neuroprotection in hypercholesterolemic rats subjected to global cerebral ischemia/reperfusion injury: In vivo and in vitro inhibition of oxidative stress. Exp Gerontol. 51:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
18	Longa EZ, Weinstein PR, Carlson S and Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:84–91. 1989. View Article : Google Scholar : PubMed/NCBI
19	Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL and Bartkowski HM: Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke. 17:1304–1308. 1986. View Article : Google Scholar : PubMed/NCBI
20	Shimamura N, Matchett G, Solaroglu I, Tsubokawa T, Ohkuma H and Zhang J: Inhibition of integrin αvbeta3 reduces blood-brain barrier breakdown in focal ischemia in rats. J Neurosci Res. 84:1837–1847. 2006. View Article : Google Scholar : PubMed/NCBI
21	Strong K, Mathers C and Bonita R: Preventing stroke: Saving lives around the world. Lancet Neurol. 6:182–187. 2007. View Article : Google Scholar : PubMed/NCBI
22	Vexler ZS, Tang XN and Yenari MA: Inflammation in adult and neonatal stroke. Clin Neurosci Res. 6:293–313. 2006. View Article : Google Scholar : PubMed/NCBI
23	Willis CL: Glia-induced reversible disruption of blood-brain barrier integrity and neuropathological response of the neurovascular unit. Toxicol Pathol. 39:172–185. 2011. View Article : Google Scholar : PubMed/NCBI
24	Wang Q, Tang XN and Yenari MA: The inflammatory response in stroke. J Neuroimmunol. 184:53–68. 2007. View Article : Google Scholar : PubMed/NCBI
25	Pickering M and O'Connor JJ: Pro-inflammatory cytokines and their effects in the dentate gyrus. Prog Brain Res. 163:339–354. 2007. View Article : Google Scholar : PubMed/NCBI
26	Kaushal V and Schlichter LC: Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci. 28:2221–2230. 2008. View Article : Google Scholar : PubMed/NCBI
27	Barone FC and Parsons AA: Therapeutic potential of anti-inflammatory drugs in focal stroke. Expert Opin Investig Drugs. 9:2281–2306. 2000. View Article : Google Scholar : PubMed/NCBI
28	Batti L and O'Connor JJ: Tumor necrosis factor-alpha impairs the recovery of synaptic transmission from hypoxia in rat hippocampal slices. J Neuroimmunol. 218:21–27. 2010. View Article : Google Scholar : PubMed/NCBI
29	Anderson CM and Swanson RA: Astrocyte glutamate transport: Review of properties, regulation and physiological functions. Glia. 32:1–14. 2000. View Article : Google Scholar : PubMed/NCBI
30	Chu K, Lee ST, Sinn DI, Ko SY, Kim EH, Kim JM, Kim SJ, Park DK, Jung KH, Song EC, et al: Pharmacological Induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke. 38:177–182. 2007. View Article : Google Scholar : PubMed/NCBI
31	Wei J, Pan X, Pei Z, Wang W, Qiu W, Shi Z and Xiao G: The beta-lactam antibiotic, ceftriaxone, provides neuroprotective potential via anti-excitotoxicity and anti-inflammation response in a rat model of traumatic brain injury. J Trauma Acute Care Surg. 73:654–660. 2012. View Article : Google Scholar : PubMed/NCBI
32	Azbill RD, Mu X and Springer JE: Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Res. 871:175–180. 2000. View Article : Google Scholar : PubMed/NCBI
33	Harvey BK, Airavaara M, Hinzman J, Wires EM, Chiocco MJ, Howard DB, Shen H, Gerhardt G, Hoffer BJ and Wang Y: Targeted over-expression of glutamate transporter 1 (GLT-1) reduces ischemic brain injury in a rat model of stroke. PLoS One. 6:e221352011. View Article : Google Scholar : PubMed/NCBI